Distinct Glycophenotypes with Abnormal Signaling Define a Subpopulation of B cells Responsible for Production of Galactose-Deficient IgA1, the Main Autoantigen in IgA Nephropathy

具有异常信号传导的独特糖表型定义了负责产生半乳糖缺陷型 IgA1(IgA 肾病的主要自身抗原)的 B 细胞亚群

基本信息

  • 批准号:
    10563618
  • 负责人:
  • 金额:
    $ 49.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-02-15 至 2027-11-30
  • 项目状态:
    未结题

项目摘要

Project Summary IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world, with 30-50% of patients progressing to end-stage kidney disease. Diagnosis is biopsy-based, with routine immunofluorescence showing IgA (co)dominant immunodeposits usually with C3 and often with IgG co-deposits. IgA in the immunodeposits is of IgA1 subclass and enriched for galactose-deficient IgA1 glycoforms (Gd-IgA1). There is currently no disease specific therapy for IgAN due to our limited understanding of the underlying mechanisms of disease progression. Recent data indicate that IgG is present in immunodeposits of virtually all IgAN patients and that it is enriched for Gd-IgA1-specific autoantibodies. Furthermore, Gd-IgA1 and anti-Gd-IgA1 IgG autoantibodies are elevated in the circulation of IgAN patients and their levels predict disease progression. Based on these, and other data, we have proposed a multi-hit hypothesis explaining the autoimmune nature of IgAN: Gd-IgA1 is elevated in circulation of IgAN patients and is recognized by anti-Gd-IgA1 IgG autoantibodies, resulting in the formation of circulating immune complexes, some of which deposit in the glomeruli, inciting renal injury. The origin of the autoantigen and the characteristics of specific cell population(s) producing Gd-IgA1 remain unknown. Recently, we showed that immortalized IgA1-secreting cells from IgAN patients produce more Gd-IgA1 autoantigen compared to the cells from healthy controls. Furthermore, only these IgAN-derived cells increase Gd-IgA1 production in response to cytokine stimulation (e.g., IL-6). Follow up analysis found enhanced STAT3 and STAT1 activation only in IgAN B cells, and that it was necessary for Gd-IgA1 production following cytokine stimulation. Single-cell transcriptome analysis of cytokine stimulated B cells from IgAN patients found IgHA1-subpopulations with abnormal expression of genes responsible for regulation of multiple cytokine signaling pathways. These IgHA1-subpopulations also exhibited abnormal alterations in the expression level of glycosyltransferase enzymes relevant to IgA1 glycosylation. Transcriptional data alone does not identify Gd-IgA1 producers. To address this, we developed a novel glycophenotyping method using lectins and recombinant anti-Gd-IgA1 IgG that can target cell surface presentation of Gd-IgA1. This process enriched for low and high Gd-IgA1-producing subpopulations, which had differential activation of transcriptional factors before and after cytokine stimulation. Using this glycophenotyping method with nucleotide conjugation, we can target Gd-IgA1-producing cells for transcriptome analysis, intracellular signaling staining, chromatin remodeling, and specific autoantigen production rates. Together, these studies will elucidate the mechanisms of autoantigen production within specific subpopulations of IgA1-producing cells and potentially lead to the development of new disease therapies for IgAN.
项目摘要 IgA肾病是世界上最常见的原发性肾小球肾炎,30%-50%的患者 进展为终末期肾病。诊断是以活检为基础的,采用常规的免疫荧光 表现为以免疫球蛋白A(共)为主的免疫沉积,通常伴有C3,常与免疫球蛋白共沉积。免疫球蛋白A在 免疫沉淀物属于IgA1亚类,富含缺乏半乳糖的IgA1糖型(Gd-IgA1)。的确有 由于我们对其潜在机制的了解有限,目前还没有针对IgAN的疾病特异性治疗方法。 疾病的进展。最近的数据表明,几乎所有IgA肾病的免疫沉淀物中都存在免疫球蛋白G。 而且它富含Gd-IgA1特异性自身抗体。此外,Gd-IgA1和抗Gd-IgA1 IgA肾病患者循环中的免疫球蛋白自身抗体升高,其水平可预测疾病的进展。 基于这些和其他数据,我们提出了一种解释自身免疫本质的多重命中假说。 IgAN患者循环中Gd-Ig A1升高并被抗Gd-Ig A1抗体识别 自身抗体,导致循环免疫复合体的形成,其中一些沉积在 肾小球,刺激肾脏损伤。自身抗原的起源和特定细胞群的特征(S) 产生Gd-IgA1仍不清楚。最近,我们发现了从IgAN中永生化的IgA1分泌细胞。 与健康对照组的细胞相比,患者产生更多的Gd-IgA1自身抗原。此外,只有 这些IgAN来源的细胞在细胞因子刺激(如IL-6)的刺激下增加Gd-IgA1的产生。关注 UP分析发现,STAT3和STAT1的激活仅在IgAN B细胞中增强,这是 细胞因子刺激后Gd-IgA1的产生。细胞因子刺激B细胞的单细胞转录组分析 IgAN患者细胞中发现IgHA1亚群相关基因异常表达 多种细胞因子信号通路的调控。这些IgHA1亚群也表现出异常 与IgA1糖基化相关的糖基转移酶表达水平的变化。 仅凭转录数据并不能确定Gd-IgA1的生产者。为了解决这个问题,我们开发了一部小说 凝集素与可靶向细胞表面的重组抗Gd-IgA1抗体的糖分型方法 Gd-IgA1的介绍。这一过程丰富了Gd-IgA1产量低和高的亚群,这些亚群具有 细胞因子刺激前后转录因子的差异激活。使用这个 用核苷酸连接的糖分型方法,可以靶向Gd-IgA1产生细胞进行转录组 分析、细胞内信号染色、染色质重塑和特异性自身抗原生成率。 总之,这些研究将阐明特定亚群中自身抗原产生的机制。 这可能会导致针对IgA肾病的新疾病疗法的开发。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Colin Robert Reily其他文献

Mitochondrial Targeted Antioxidant MitoQ Modulates Smad2/3 and β-catenin Signaling Pathways in the Prevention of Diabetes Induced Kidney Damage
  • DOI:
    10.1016/j.freeradbiomed.2010.10.083
  • 发表时间:
    2010-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Colin Robert Reily
  • 通讯作者:
    Colin Robert Reily

Colin Robert Reily的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Colin Robert Reily', 18)}}的其他基金

Abnormal cytokine response and autoantigen production in IgA-producing subpopulations in IgA nephropathy
IgA 肾病中 IgA 产生亚群的异常细胞因子反应和自身抗原产生
  • 批准号:
    9807239
  • 财政年份:
    2019
  • 资助金额:
    $ 49.06万
  • 项目类别:
Abnormal STAT3 signaling and aberrant O-glycosylation of IgA1 in IgA nephropathy
IgA 肾病中 STAT3 信号异常和 IgA1 异常 O-糖基化
  • 批准号:
    8949844
  • 财政年份:
    2015
  • 资助金额:
    $ 49.06万
  • 项目类别:
Abnormal STAT3 Signaling and Aberrant O-Glycosylation of IgA1 in IgA Nephropathy
IgA 肾病中 STAT3 信号异常和 IgA1 异常 O-糖基化
  • 批准号:
    10384158
  • 财政年份:
    2015
  • 资助金额:
    $ 49.06万
  • 项目类别:
Abnormal STAT3 signaling and aberrant O-glycosylation of IgA1 in IgA nephropathy
IgA 肾病中 STAT3 信号异常和 IgA1 异常 O-糖基化
  • 批准号:
    9750059
  • 财政年份:
    2015
  • 资助金额:
    $ 49.06万
  • 项目类别:
Abnormal STAT3 signaling and aberrant O-glycosylation of IgA1 in IgA nephropathy
IgA 肾病中 STAT3 信号异常和 IgA1 异常 O-糖基化
  • 批准号:
    9341290
  • 财政年份:
    2015
  • 资助金额:
    $ 49.06万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了